(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
On July 10, 2013, Omni Bio Pharmaceutical, Inc. (OTCPK:OMBP) announced it will be collaborating with the University of Michigan Cancer Center (UMCC) and Leukemia and Lymphoma Society (LLS) to study plasma-derived alpha-1 antitrypsin (p-AAT) for the treatment of complications following bone marrow transplantation, or as it's more commonly referred to, Graft vs. Host Disease (GvHD). The Phase II multicenter pilot study (ClinicalTrials.gov # NCT01700036) will be funded almost entirely by UMCC and LLS. Omni Bio will supply logistical support and drug will be supplied by CSL Behring.
The principal investigator of the study is Dr. Ravan R....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|